Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence

Final draft guidance: 1

Committee papers (PDF 1.45 MB)

Public committee slides (PowerPoint 1.86 MB)

Final draft guidance (PDF 266 KB)

Draft guidance

Draft guidance (downloadable version) (PDF 258 KB)

Draft guidance (online commenting)

Committee papers (PDF 9.19 MB)

Equality impact assessment (downloadable version) (PDF 123 KB)

Final scope (PDF 196 KB)

Final stakeholder list (PDF 170 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 360 KB)

Draft scope post referral (PDF 203 KB)